Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Abiraterone + HRS-1167 + Prednisone |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Abiraterone | Zytiga | CB7630 | Hormone - Anti-androgens 57 | Zytiga (abiraterone) inhibits cytochrome P-450c17, resulting in decreased androgen synthesis (PMID: 25560485). Zytiga (abiraterone) is FDA approved for patients with metastatic castration-resistant prostate cancer (FDA.gov). |
| HRS-1167 | M-9466|M 9466|HRS1167|HRS 1167|M9466 | PARP-1 Inhibitor 13 | HRS-1167 inhibits PARP1, which potentially reduces tumor growth (J Clin Oncol 42, 2024 (suppl 16; abstr 3154)). | |
| Prednisone | Adasone | Dehydrocortisone | Adasone (prednisone) is a corticosteroid which functions as an immunosuppressant and anti-inflammatory agent and which may stimulate apoptosis in tumor cells (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06421935 | Phase I | HRS-1167 + M1774 HRS-1167 Abiraterone + HRS-1167 + Prednisone | M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501) | Recruiting | USA | ESP | AUS | 2 |